肝脏 ›› 2025, Vol. 30 ›› Issue (9): 1238-1243.

• 肝肿瘤 • 上一篇    下一篇

血清miR-524-5p和miR-411-5p表达与肝癌早期诊断及临床预后的关系

陈洁, 田乐, 伍锞, 张千   

  1. 435400 黄冈 武穴市第一人民医院检验科
  • 收稿日期:2024-06-30 出版日期:2025-09-30 发布日期:2025-11-05
  • 通讯作者: 张千,Email:o14hsl@163.com

Value of serum miR-524-5p and miR-411-5p expression in early diagnosis and clinical prognosis with liver cancer

CHEN Jie, TIAN Le, WU Ke, ZHANG Qian   

  1. Department of Clinical Laboratory, The First People's Hospital of Wuxue City, Huanggang 435400, China
  • Received:2024-06-30 Online:2025-09-30 Published:2025-11-05
  • Contact: ZHANG Qian,Email:o14hsl@163.com

摘要: 目的 探讨血清miR-524-5p和miR-411-5p表达与肝癌(LC)早期诊断及临床预后的关系。方法 选取本院2018年10月至2020年10月收治的96例LC患者作为LC组,另选取同期医院96名健康体检者作为对照组。检测两组患者血清miR-524-5p和miR-411-5p表达水平;分析血清miR-524-5p和miR-411-5p水平对LC发生的诊断效能及预后的关系;分析影响LC患者预后的因素。结果 与对照组相比,LC组的miR-524-5p表达水平明显降低(0.76±0.19 比1.01±0.21,t=8.625,P<0.001),miR-411-5p表达水平明显降低(0.79±0.23 比1.01±0.18,t=7.380,P<0.001)。血清miR-524-5p、miR-411-5p二者联合诊断LC发生的AUC最高为0.850,优于各自单独诊断(Z二者联合-miR-524-5p=2.126、P=0.034,Z二者联合-miR-411-5p=3.577、P<0.001)。LC患者血清miR-524-5p、miR-411-5p表达与TNM分期、淋巴结转移、浸润深度、分化程度有关(P<0.05)。血清miR-524-5p、miR-411-5p高表达LC患者3年生存率高于miR-524-5p、miR-411-5p低表达患者(χ2=4.525、5.596,P=0.033、0.018)。多因素Cox分析结果显示,miR-524-5p、miR-411-5p是LC患者预后的保护因素(P<0.05),TNM分期、淋巴结转移、浸润深度、分化程度是LC患者预后的危险因素(P<0.05)。结论 LC患者血清miR-524-5p、miR-411-5p表达水平降低,其表达与临床病理特征和预后有关,二者联合用于诊断LC发生的效果最好。

关键词: 肝癌, miR-524-5p, miR-411-5p, 早期诊断, 预后

Abstract: Objective To explore the relationship between serum miR-524-5p and miR-411-5p expression in early diagnosis and clinical prognosis of patients with liver cancer (LC). Methods From October 2018 to October 2020, 96 patients with LC admitted to our hospital were collected as the LC group, and 96 healthy individuals from the same hospital were regarded as the control group. The expression levels of serum miR-524-5p and miR-411-5p were detected. The diagnostic efficacy of serum miR-524-5p and miR-411-5p levels in LC was analyzed. The relationship between the expression of serum miR-524-5p and miR-411-5p and prognosis in LC patients was analyzed. Further, the factors affecting the prognosis of LC patients were investigated. Results Compared with the control group, the expression level of miR-524-5p in LC group was significantly lower (0.76±0.19 vs. 1.01±0.21, t=8.625, P<0.001), and the expression level of miR-411-5p was also significantly lower (0.79±0.23 vs. 1.01±0.18, t=7.380, P<0.001). The area under the curve (AUC) for the combined diagnosis of LC using serum miR-524-5p and miR-411-5p was the highest at 0.850, which was better than the individual diagnosis of serum miR-524-5p and miR-411-5p (Zcombination-miR-524-5p=2.126, P=0.034, Zcombination-miR-411-5p=3.577, P<0.001). The expression level of miR-524-5p and miR-411-5p in LC patients was related to TNM staging, lymph node metastasis, depth of infiltration, and degree of differentiation (P<0.05). The 3-year survival rate of LC patients with high expression level of miR-524-5p and miR-411-5p was higher than that of patients with low expression of miR-524-5p and miR-411-5p (χ2=4.525, 5.596, P=0.033, 0.018). Multivariate Cox analysis showed that miR-524-5p and miR-411-5p were protective factors affecting the prognosis of LC patients (P<0.05), and TNM stage, lymph node metastasis, invasion depth and differentiation degree were risk factors affecting the prognosis of LC patients (P<0.05). Conclusion The expression levels of serum miR-524-5p and miR-411-5p are decreased in LC patients, and their expressions are related to clinicopathological features and prognosis. The combination of them has the best efficacy in diagnosing LC.

Key words: Liver cancer, MiR-524-5p, MiR-411-5p, Early diagnosis, Prognosis